The use of fecal calprotectin and lactoferrin in patients with IBD. Review

Acta Gastro-Enterologica Belgica

Volumn 76, Issue 3, 2013, Pages 322-328

  Stragier, Elisabeth ^a   van Assche, Gert ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Calprotectin; Fecal markers; IBD; Lactoferrin

Indexed keywords

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 84886837149     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. GISBERT J.P., MCNICHOLL A.G. Questions and answers on the role of fecal calprotectin as a biological marker in inflammatory bowel disease. Dig. Liver Dis., 2009, 41 (1): 56-66.
2. VERMEIRE S., VAN ASSCHE G., RUTGEERTS P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut, 2006, 55: 426-431.
3. VERMEIRE S., VAN ASSCHE G., RUTGEERTS P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat. Clin. Pract. Gastroenterol. Hepatol., 2005, 2: 580-586.
4. SHINE B. et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin. Chim. Acta, 1985, 148: 105-109.
5. BEATLLE R.M. et al. Indications for investigation of chronic gastrointestinal symptoms. Arch. Dis. Child., 1995, 73: 354-355.
6. POULLIS A.P., ZAR S., SUNDARAM K.K. et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation-and diarrhea-predominant functional bowel disorders. Eur. J. Gastroenterol. Hepatol., 2002, 14: 409-412.
7. Schoepfer A.M. et al. Ulcerative colitis: Correlation of the Rachmilewitz Endoscopic Activity Index with fecal Calprotectin, Clinical Activity, C-reactive protein, and Blood leukocytes. Inflamm. Bowel Dis., 2009, 15 (12): 1851-1858.
8. Schoepfer A.M. et al. Fecal calprotectin correlates more closely with de Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood leukocytes, and the CDAI. Am. J. Gastroenterol., 2010, 105 (1): 162-169.
9. LEWIS J.D. C-reactive protein: anti-placebo or predictor of response. Gastroenterology, 2005, 129: 1114-1116.
10. RICANEK P. et al. Evaluation of disease activity in IBD at the diagnosis by the use of clinical, biochemical, and fecal markers. Scandinavian Journal of Gastroenterology, 2011, 46: 1081-1091.
11. SOLEM C.A. et al. Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease (IBD). Inflamm. Bowel Dis., 2005, 11: 707-712.
12. HO G.T. et al. Fecal calprotectin predicts the Clinical Course of Acute Severe Ulcerative Colitis. Am. J. Gastroenterol., 2009, 104: 673-678.
13. CONSIGNY Y., MODIGLIANI R., COLOMBEL J.F. et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm. Bowel Dis., 2006, 12 (7): 551-557.
14. OUSSALAH A., CHEVAUX J.B., FAY R. et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am. J. Gastroenterol., 2010, 105: 1142-1149.
15. BITTON A., DOBKIN P.L., EDWARDES M.D. et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut, 2008, 57: 1386-1392.
16. PAPI C., FESTA V., LEANDRO G. et al. Long-term outcome of Crohn's disease following corticosteroid-induced remission. Am. J. Gastroenterol., 2007, 102: 814-819.
17. BITTON A., PEPPERCORN M.A., ANTONIOLI D.A. et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology, 2001, 120: 13-20.
18. JÜRGENS M., MAHACHIE J. et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin. Gastroenterol. Hepatol., 2011 May, 9 (5): 421-427.
19. LOUIS E., VERMEIRE S., RUTGEERTS P. et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism. Scand. J. Gastroenterol., 2002, 37: 818-824.
20. COLOMBEL J.F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med, 2010 Apr 15, 362 (15): 1383-1395.
21. ANGRIMAN I. et al. 5 Enzymes in faeces: useful markers of chronic inflammatory bowel disease. Clin. Chim. Acta, 2007, 381: 63-68.
22. FAGERBERG U.L. et al. Fecal calprotectin levels in children studied with an improved assay. J. Pediatric Gastroenterol. Nutr., 2003, 37: 468-472.
23. VON ROON A.C. et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am. J. Gastroenterol., 2007, 102: 803-813.
24. VAN RHEENEN P.F. et al. Fecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ, 2010, 341: 3369.
25. LANGHORST J., ELSENBRUCH S., KOELZER J. et al. Non-invasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: Performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP and clinical indices. Am. J. Gastroenterol., 2008, 103: 162-169.
26. POULLIS A. et al. Review article: fecal markers in the assessment of activity in inflammatory bowel disease. Aliment. Pharmacol. Ther., 2002, 16: 675-681.
27. COSTA F. et al. Role of fecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis., 2003, 35: 642-647.
28. MONTALTO M. et al. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am. J. Gastroenterol., 2007, 102: 132-136.
29. XIANG J.-Y. et al. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J. Gastroenterol., 2008, 14 (1): 53-57.
30. JONES J., LOFTUS E.V. JR., PANACCIONE R., CHEN L.S., PETERSON S., MCCONNELL J. et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin. Gastroenterol. Hepatol., 2008, 6: 1218-1224.
31. SIPPONEN T., SAVILAHTI E., KOLHO K. et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn'sdisease activity index and endoscopic findings. Inflamm. Bowel Dis., 2008, 14: 40-46.
32. SCHOEPFER A., VAVRICKA S. et al. Monitoring inflammatory bowel disease activity: Clinical activity is judged to be more relevant than endo-scopic severity or biomarkers. Journals of Crohn's and Colitis, 2012, 6 (4): 412-418.
33. GISBERT J.P. et al. Fecal Calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm. Bowel Dis., 2009, 15: 1190-1198.
34. COSTA F. et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut, 2005, 54: 364-368.
35. GARCIA-SANCHEZ V. et al. Does fecal calprotectin predict relapse in patients with Crohn's diease and ulcerative colitis? Journal of Crohn's and colitis, 2010, 4: 144-152.
36. ROSETH A.G., AADLAND E., GRZYB K. Normalization of fecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand. J. Gastroenterol., 2004, 39: 1017-1020.
37. SIPPONEN T. et al. Fecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Cohn's disease treatment. Scand. J. Gastroenterol., 2009.
38. SIPPONEN T. et al. Fecal Calprotectin, Lactoferrin, and Endoscopic Disease Activity in Monitoring Anti-TNF-alpha Therapy for Crohn's Disease. Inflamm. Bowel Dis., 2008.
39. WAGNER M., PETERSON CG., RIDEFELT P., SANGFELT P., CARLSON M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J. Gastroenterol., 2008, 14: 5584-5589.
40. DE VOS M., DEWIT O. et al. Fast and sharp decrease in calprotectin predicts remission by Infliximab in anti-TNF naïve patients with ulcerative colitis. Journal of Crohn's and colitis, 2012, 6: 557-562.
41. RUTGEERTS P., SANDBORN W.J. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 353: 2462-2476.
42. KANE S.V. et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am. J. Gastroenterol., 2003, 98: 1309-1314.
43. VIEIRA A., FANG C.B. et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BCD Research Notes, 2009, 2: 221.